UPB (Upstream Bio) Total Operating Expense: $175.29 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UPB Upstream Bio Inc UPB
10 GF Score
Price $6.99
! 1 Warning Sign
View Full Analysis

What is Upstream Bio Total Operating Expense?

Upstream Bio UPB -3.04% 10 Total Operating Expense is $175.29 Mil as of Mar. 2026. GuruFocus rates UPB with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Upstream Bio's Total Operating Expense for the three months ended in Mar. 2026 was $44.65 Mil. Upstream Bio's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $175.29 Mil.

Upstream Bio Total Operating Expense Related Terms

Upstream Bio Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Upstream Bio's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Upstream Bio Total Operating Expense Chart

Upstream Bio Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Operating Expense
25.12 42.49 80.13 163.22

Upstream Bio Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.58 45.28 38.52 46.84 44.65
UPB
10GF Score
Upstream Bio Inc UPB
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Upstream Bio Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $175.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $175.29 Mil mean?
Upstream Bio (UPB) has a Total Operating Expense of $175.29 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Upstream Bio and its competitors.
Is Upstream Bio's Total Operating Expense too high?
Upstream Bio's current Total Operating Expense is $175.29 Mil. Overall, Upstream Bio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Upstream Bio's Total Operating Expense compare to OABI and VNDA?
Upstream Bio's Total Operating Expense of $175.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Upstream Bio and its competitors. Upstream Bio's current Total Operating Expense is $175.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Upstream Bio stock overvalued right now?
Upstream Bio (UPB) has a current Total Operating Expense of $175.29 Mil. The current Total Operating Expense is $175.29 Mil. Upstream Bio's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Upstream Bio (UPB), the current Total Operating Expense is $175.29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Upstream Bio Business Description

Address 890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
10GF Score

Get the complete analysis for UPB

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.99
Price